Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.54 |
| ▸ | NPY1R | P25929 | 3/20 | 0.53 |
| ▸ | NPY2R | P49146 | 3/20 | 0.53 |
| ▸ | NPY4R | P50391 | 3/20 | 0.53 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 6/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30264689 | 0.96 | NPY1R (0.55) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL30264776 | 0.96 | NPY1R (0.55) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL31184624 | 0.94 | ACE (0.55) | ACEECE1 | |
| SCHEMBL29511163 | 0.94 | ACE (0.55) | ACEECE1 | |
| SCHEMBL29476594 | 0.94 | ACE (0.55) | ACEECE1 | |
| SCHEMBL30265032 | 0.94 | NPY1R (0.53) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL30264740 | 0.94 | NPY1R (0.53) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL30264615 | 0.94 | NPY1R (0.53) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL30264762 | 0.94 | IL23R (0.55) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL30264981 | 0.92 | ACE (0.53) | NPY1RNPY2RNPY4RACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | ERAP2 562/4885ERAP1 496/4885LNPEP 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.